Document Classification

Section Type: METHODS

Text: After 2 weeks of treatment based on previous therapy (ICSs and short-acting bronchodilators allowed during the run-in period), patients received one of the following treatments administered twice daily : budesonide/formoterol pMDI 160/4. 5 microg x two inhalations (320/9 microg) ; budesonide/formoterol pMDI 80/4. 5 microg x two inhalations (160/9 microg) ; budesonide pMDI 160 microg x two inhalations (320 microg) plus formoterol DPI 4. 5 microg x two inhalations (9 microg) ; budesonide pMDI 160 microg x two inhalations (320 microg) ; formoterol DPI 4. 5 microg x two inhalations (9 microg) ; or placebo.